Lexaria To Begin Diabetes And Weight Loss Animal Study WEIGHT-A24-1
Lexaria To Begin Diabetes And Weight Loss Animal Study WEIGHT-A24-1
Lexaria 将开始糖尿病和减肥动物研究 WEIGHT-A24-1
Multiple DehydraTECH-GLP-1 and DehydraTECH-CBD formulations to be tested
Chronic dosing over a 12-week treatment period
Will assess weight loss and blood glucose level control
Efficacy through possible brain absorption delivery enhancement to be assessed
多种 Dehydratech-GLP-1 和 Dehydratech-CBD 配方有待测试
在 12 周的治疗期内长期给药
将评估体重减轻和血糖水平控制
通过可能增强大脑吸收传递的功效有待评估
KELOWNA, BC / ACCESSWIRE / March 5, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces details of an 8-week animal study WEIGHT-A24-1 (the "Study") to examine diabetes and weight loss effects of DehydraTECH-processed glucagon-like peptide 1 ("GLP-1") drugs and DehydraTECH-processed cannabidiol, alone and in combination.
不列颠哥伦比亚省基洛纳/ACCESSWIRE/2024年3月5日/药物递送平台领域的全球创新者Lexaria Bioscience Corp.（纳斯达克股票代码：LEXXW）（“公司” 或 “Lexaria”）公布了一项为期8周的动物研究 WEIGHT-A24-1（“研究”）的细节，该研究旨在研究脱水处理的胰高血糖素样肽 1（“GLP-1”）对糖尿病和减肥的作用药物和脱水剂加工的大麻二酚，单独或联合使用。
The contract for the Study has been awarded to...
该研究的合同已授予...
登录免费看全文
登录/注册